Nema internetske veze — prikazuje se spremljena verzija stranice.

Sanofi ADR

USUSD
← Na filtar dionica

Sanofi ADR (PA:SAN) — Biotechnology: Pharmaceutical Preparations. Broj burzi na kojima se trguje dionicama tvrtke: 6. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.

O tvrtki

Web-stranica
sanofi.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sjedište
PARIS, France
Glavni direktor
Paul Hudson
Zaposlenici
106 566
Osnovana
2004
Na burzi od
03.01.2000 (PA:SAN)
Dionice u optjecaju
1.22 mlrd. na dan 2025-12-31
Slobodno prenosive dionice
2.16 mlrd.
Tržišna kapitalizacija
98.67 mlrd. USD
Insajderi
0%
Institucionalni ulagači
8.02%
Djelatnost (SIC)
Pharmaceutical Preparations
Pravni oblik
QVPB
ISIN
FR0000120578
LEI
549300E9PC51EN656011
Omjer isplate
0%
FCF
10.8 mlrd. EUR
Dug
18.7 mlrd. EUR
1.0 g. FCF
Dividendni staž
23 g.
Zarada, FCF i isplaćene dividende — za 12 mjeseci do 31.12.2025 (najnovije izvješće tvrtke).
Opis

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Burze i oznake

BurzaOznakaValutaCijenaVrsta
US USA StocksSNYNF OTCUSD78.99 -1.19%obične dionice
LSE London Stock Exchange0O59 IOBEUR71.63 +0.72%obične dionice
MI Borsa Italiana (Milan)1SAN dodatnaEUR71.64 +0.90%obične dionice
PA Euronext ParisSAN glavnaEUR71.52 +0.83%obične dionice
VI Vienna Stock ExchangeSANO dodatnaEUR71.3 +1.03%obične dionice
XETRA XetraSNW dodatnaEUR71.78 -1.21%obične dionice

Cijena za 3 mjeseca

dan rasta dan pada ex-dividendni datum datum isplatePrijeđite mišem / dodirnite dan — cijene otvaranja, zatvaranja, najviša i najniža

Dividende

Zadnjih 12 mjeseci, PA:SAN: 4.12 EUR (1 ispl.)

Sanofi ADR (SAN) isplaćuje dividende jednom godišnje. U posljednjih 12 mjeseci isplaćeno je 4.12 EUR po dionici (isplate: 1). To je otprilike 5.76% trenutne cijene dionice. Prema povijesti isplata, sljedeći datum ex-dividende očekuje se oko 04.05.2027. Godine neprekinutih dividendi: 23.

Ex-datumIsplataIznos%VrstaOznaka
2026-05-052026-05-074.1200 EUR5.8/5.8 %godišnjiPA:SAN
2025-05-122025-05-143.9200 EUR5.5/5.5 %godišnjiPA:SAN
2024-05-13—3.7600 EUR5.3/10.2 %godišnjiPA:SAN
2023-05-30—3.5600 EUR5.0/5.0 %godišnjiPA:SAN
2022-05-06—3.3300 EUR4.7/4.7 %godišnjiPA:SAN

Vijesti ovog tjedna

Još nema vijesti s web-stranice tvrtke.

oglas

Najveći imatelji

ImateljUdioDioniceDatum izvješća
Dodge & Cox Inc.10.54%28.09 mil.2026-06-30
Dodge & Cox Funds-Dodge…7.84%20.9 mil.2026-06-30
Morgan Stanley4.02%10.7 mil.2026-06-30
Fisher Asset Management,…3.99%10.63 mil.2026-06-30
Bank of America Corporat…3%8.01 mil.2026-06-30
Invesco Ltd.2.55%6.8 mil.2026-06-30
JPMORGAN CHASE & CO2.47%6.57 mil.2026-06-30
Mondrian Investment Part…2.07%5.52 mil.2026-06-30
Brandes Investment Partn…1.55%4.14 mil.2026-06-30
AIM Sector Funds (Invesc…1.51%4.03 mil.2026-04-30
Federated Hermes, Inc.1.44%3.85 mil.2026-06-30
Boston Partners1.44%3.84 mil.2026-06-30
VANGUARD STAR FUNDS-Vang…1.31%15.85 mil.2026-07-31
Putnam ETF Trust-Putnam…1.26%3.36 mil.2026-05-31
VANGUARD TAX-MANAGED FUN…0.87%10.53 mil.2026-06-30
iShares Trust-iShares Co…0.67%8.11 mil.2026-08-31
Dodge & Cox Funds-Dodge…0.63%1.67 mil.2026-06-30
AMERICAN MUTUAL FUND0.59%1.58 mil.2026-06-30
American Century Capital…0.37%976 5612026-06-30
Bridge Builder Trust-Bri…0.36%967 1002026-06-30
Fidelity Concord Street…0.35%4.24 mil.2026-07-31
VanEck ETF Trust-VanEck…0.35%938 5612026-08-31
Dodge & Cox Funds-Dodge…0.33%4.04 mil.2026-06-30
iShares Trust-iShares MS…0.32%3.89 mil.2026-08-31
Capital World Growth & I…0.3%3.67 mil.2026-06-30
-Victory Pioneer Core Eq…0.3%799 4872026-06-30
Fidelity Covington Trust…0.3%797 1842026-08-31
NEW PERSPECTIVE FUND0.29%3.56 mil.2026-06-30
Federated Hermes Eqy. Fd…0.29%3.48 mil.2026-07-31
Bridge Builder Trust-Bri…0.29%3.44 mil.2026-06-30
Pacer Advisors, Inc.0.1%1.16 mil.2026-06-30
Generali Investments Cee…0%29 3392026-06-30
Paradigm Asset Managemen…0%19 2002026-06-30
Gamma Investing LLC0%582026-06-30
L'Oréal———